2 completed, 2 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Scioderm, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa SD-101-6.0 cream - Epidermolysis Bullosa | Phase 3 | Terminated | Scioderm, Inc. | 152 | 2015-06-09 | 2019-09-27 |
| ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa SD-101-6.0 cream, Placebo (SD-101-0.0) cream - Epidermolysis Bullosa | Phase 3 | Completed | Scioderm, Inc. | 169 | 2015-03-11 | 2020-04-09 |
| Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa SD-101 dermal cream (6%) - Epidermolysis Bullosa | Phase 2 | Terminated | Scioderm, Inc. | 42 | 2014-03-26 | 2019-11-04 |
| Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) - Epidermolysis Bullosa | Phase 2 | Completed | Scioderm, Inc. | 48 | 2014-01-06 | 2020-01-13 |
United States (4) · Australia (2) · Austria (2) · France (2) · Germany (2) · Israel (2) · Lithuania (2) · Netherlands (2) · Poland (2) · Serbia (2) · Spain (2) · United Kingdom (2) · Italy (1)
2014 (2)